Analyzing tumor metabolism in vivo

Annual Review of Cancer Biology

Volumn 1, Issue , 2017, Pages 99-117

  Faubert, Brandon ^a   Deberardinis, Ralph J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer metabolism; Magnetic resonance imaging; Mass spectrometry; Metabolic flux analysis; Metabolomics; Positron emission tomography

Indexed keywords

EID: 85030558263     PISSN: None     EISSN: 24723428     Source Type: Book Series    
DOI: 10.1146/annurev-cancerbio-050216-121954     Document Type: Article

References (109)

1. Almendro V, Marusyk A, Polyak K. 2013. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. Mech. Dis. 8:277-302
2. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, et al. 2012. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med. 4:116ra4
3. Barker HE, Paget JT, Khan AA, Harrington KJ. 2015. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15:409-25
4. Bathen TF, Heldahl MG, Sitter B, Vettukattil R, Bofin A, et al. 2011. In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response. MAGMA 24:347-57
5. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, et al. 2000. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-51
6. Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJ. 2016. A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur. J. Cancer 55:81-97
7. Boroughs LK, DeBerardinis RJ. 2015. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17:351-59
8. Buescher JM, Antoniewicz MR, Boros LG, Burgess SC, Brunengraber H, et al. 2015. A roadmap for interpreting 13C metabolite labeling patterns from cells. Curr. Opin. Biotechnol. 34:189-201
9. Burrell RA,McGranahanN, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501:338-45
10. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:85-95
11. Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A,MenaraM, et al. 2014. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum. Mol. Genet. 23:2440-46
12. Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, et al. 2013. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat. Commun. 4:2429
13. Cheng T, Sudderth J, Yang C,Mullen AR, Jin ES, et al. 2011. Pyruvate carboxylase is required for glutamineindependent growth of tumor cells. PNAS 108:8674-79
14. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, et al. 2012. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18:624-29
15. Comerford SA, Huang Z,Du X,Wang Y, Cai L, et al. 2014. Acetate dependence of tumors. Cell 159:1591-602
16. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, et al. 2013. Macropinocytosis of protein is an amino acid supply route in Ras-Transformed cells. Nature 497:633-37
17. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. 2009. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-44
18. Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, et al. 2016. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23:517-28
19. DeBerardinis RJ. 2015. Analyzingmetabolism in biological systems. In Navigating Metabolism, ed.NSChandel, pp. 223-31. Cold Spring Harbor, NY: Cold Spring Harb. Lab. Press
20. DeBerardinis RJ, Cheng T. 2010. Q?s next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:313-24
21. DeBerardinis RJ,Mancuso A, Daikhin E, Nissim I, YudkoffM, et al. 2007. Beyond aerobic glycolysis: Transformed cells can engage in glutaminemetabolism that exceeds the requirement for protein and nucleotide synthesis. PNAS 104:19345-50
22. Delikatny EJ, Chawla S, Leung DJ, Poptani H. 2011. MR-visible lipids and the tumor microenvironment. NMR Biomed. 24:592-611
23. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, et al. 2012. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci. Transl. Med. 4:116ra5
24. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. 2014. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510:298-302
25. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, et al. 2009. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 8:41
26. Farber S, DiamondLK, Mercer RD, SylvesterRF Jr.,Wolff JA. 1948. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. 238:787-93
27. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disruptTET2function, and impair hematopoietic differentiation. Cancer Cell 18:553-67
28. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 2008. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn. Reson. Med. 60:253-57
29. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, et al. 2009. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. PNAS 106:19801-6
30. Gambhir SS. 2002. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2:683-93
31. Gillies RJ, Morse DL. 2005. In vivo magnetic resonance spectroscopy in cancer. Annu. Rev. Biomed. Eng. 7:287-326
32. Glunde K, Bhujwalla ZM. 2011. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin. Oncol. 38:26-41
33. Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, et al. 2012. The clinical use of PET with 11C-Acetate. Am. J. Nucl. Med. Mol. Imaging 2:33-47
34. Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, et al. 2016. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29:104-16
35. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-74
36. HayesGM,Simko J, Holochwost D, KuchinskyK, Busch R, et al. 2012. Regional cell proliferation inmicrodissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Clin. Cancer Res. 18:3250-60
37. Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, et al. 2016. Metabolic heterogeneity in human lung tumors. Cell 164:681-94
38. Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, et al. 2008. Stereotactic biopsy in gliomas guided by 3-Tesla 1H-chemical-shift imaging of choline. Stereotact. Funct. Neurosurg. 86:300-7
39. Herranz D, Ambesi-Impiombato A, Sudderth J, Sanchez-Martin M, Belver L, et al. 2015. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat. Med. 21:1182-89
40. Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, et al. 2016. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev. Cell 36:540-49
41. Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, et al. 2015. Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma. PLOS ONE 10:e0141506
42. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, et al. 2011. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab. 14:131-42
43. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, et al. 2005. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143-53
44. Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, et al. 2016. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532:255-58
45. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. 2013. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 493:689-93
46. Kaelin WG Jr., McKnight SL. 2013. Influence of metabolism on epigenetics and disease. Cell 153:56-69
47. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, et al. 2013. Hypoxic and Ras-Transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. PNAS 110:8882-87
48. Keshari KR, Kurhanewicz J, Bok R, Larson PE, Vigneron DB, Wilson DM. 2011. Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. PNAS 108:18606-11
49. Ko ES, Kim JH, Lim Y, Han BK, Cho EY, Nam SJ. 2016. Assessment of invasive breast cancer heterogeneity using whole-Tumor magnetic resonance imaging texture analysis: correlations with detailed pathological findings. Medicine 95:e2453
50. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, et al. 2011. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 13:81-97
51. Kurhanewicz J, VigneronDB, Hricak H, Narayan P, Carroll P, Nelson SJ. 1996. Three-dimensional H-1MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 198:795-805
52. Lee DY, Kind T, Yoon YR, Fiehn O, Liu KH. 2014. Comparative evaluation of extraction methods for simultaneous mass-spectrometric analysis of complex lipids and primary metabolites from human blood plasma. Anal. Bioanal. Chem. 406:7275-86
53. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, et al. 2013. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23:739-52
54. Li B, Qiu B, Lee DS,Walton ZE, Ochocki JD, et al. 2014. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513:251-55
55. Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, et al. 2011. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J. Nucl. Med. 52:1947-55
56. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-78
57. Lu W, Bennett BD, Rabinowitz JD. 2008. Analytical strategies for LC-MS-based targeted metabolomics. J. Chromatogr. B. 871:236-42
58. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, et al. 2005. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120:237-48
59. Lunt SY, Vander Heiden MG. 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27:441-64
60. Lyssiotis CA, Cantley LC. 2014. Acetate fuels the cancer engine. Cell 159:1492-94
61. Maher EA, Marin-Valencia I, Bachoo RM,Mashimo T, Raisanen J, et al. 2012. Metabolism of [U-13C]glucose in human brain tumors in vivo. NMR Biomed. 25:1234-44
62. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, et al. 2012. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15:827-37
63. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, et al. 2014. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159:1603-14
64. Mullen AR, DeBerardinis RJ. 2012. Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol. Metab. 23:552-59
65. Nelson SJ, Kurhanewicz J, VigneronDB, Larson PE,Harzstark AL, et al. 2013. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci. Transl. Med. 5:198ra08
66. O?Brien PJ, LeeM, Spilker ME, Zhang CC, Yan Z, et al. 2013. Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging. Cancer Metab. 1:4
67. O?Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. 2015. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin. Cancer Res. 21:249-57
68. Olivares O, Dabritz JH, King A, Gottlieb E, Halsey C. 2015. Research into cancer metabolomics: Towards a clinical metamorphosis. Semin. Cell Dev. Biol. 43:52-64
69. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
70. Pavlova NN, Thompson CB. 2016. The emerging hallmarks of cancer metabolism. Cell Metab. 23:27-47
71. Pollard PJ, Wortham NC, Tomlinson IP. 2003. The TCA cycle and tumorigenesis: The examples of fumarate hydratase and succinate dehydrogenase. Ann. Med. 35:632-39
72. Pope WB, Prins RM, Thomas MA, Nagarajan R, Yen KE, et al. 2012. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J. Neuro-Oncology 107:197-205
73. Rabinowitz JD, White E. 2010. Autophagy and metabolism. Science 330:1344-48
74. Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, et al. 2008. Germline SDHB mutations and familial renal cell carcinoma. J. Natl. Cancer Inst. 100:1260-62
75. Rodrigues TB, Serrao EM, Kennedy BW, Hu DE, Kettunen MI, Brindle KM. 2014. Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose. Nat. Med. 20:93-97
76. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, et al. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626-30
77. Sabharwal SS, Schumacker PT. 2014. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles? heel? Nat. Rev. Cancer 14:709-21
78. Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, et al. 2015. Combined use of 18F-FDG and 18F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: A dynamic PET/CT study. Am. J. Nucl. Med. Mol. Imaging 5:127-42
79. Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, et al. 2006. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 238:42-53
80. Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, et al. 2015. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27:57-71
81. Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, Henriques da Costa AS, et al. 2016. Fumarate is an epigenetic modifier that elicits epithelial-To-mesenchymal transition. Nature. In press. doi: 10.1038/nature19353
82. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, et al. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-αprolyl hydroxylase. Cancer Cell 7:77-85
83. Sellers K, Fox MP, Bousamra M, Slone SP, Higashi RM, et al. 2015. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Investig. 125:687-98
84. Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, et al. 2015. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. PNAS 112:6539-44
85. Sonveaux P, Vegran F, Schroeder T,Wergin MC, Verrax J, et al. 2008. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Investig. 118:3930-42
86. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. 2009. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-14
87. Stroobants S, Verschakelen J, Vansteenkiste J. 2003. Value of FDG-PET in the management of non-small cell lung cancer. Eur. J. Radiol. 45:49-59
88. Sullivan LB, Chandel NS. 2014. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2:17
89. Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, et al. 2013. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. J. Radiat. Res. 54:1078-84
90. Tardito S,Oudin A, Ahmed SU, Fack F, Keunen O, et al. 2015. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17:1556-68
91. Tognarelli JM, Dawood M, Shariff MI, Grover VP, Crossey MM, et al. 2015. Magnetic resonance spectroscopy: principles and techniques: lessons for clinicians. J. Clin. Exp. Hepatol. 5:320-28
92. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, et al. 2002. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30:406-10
93. Trim PJ, Snel MF. 2016. Small molecule MALDI MS imaging: current technologies and future challenges. Methods 104:127-41
94. Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, et al. 2015. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci. Transl. Med. 7:274ra17
95. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. 1993. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J. Clin. Oncol. 11:2101-11
96. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, et al. 2013. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622-26
97. Warburg O. 1956. On the origin of cancer cells. Science 123:309-14
98. Warburg O,Wind F, Negelein E. 1927. The metabolism of tumors in the body. J. Gen. Physiol. 8:519-30
99. Ward PS, Thompson CB. 2012. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308
100. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, et al. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.PNAS105:18782-87
101. Xiao M, Yang H, Xu W, Ma S, LinH, et al. 2012. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26:1326-38
102. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. 1995. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J. Nucl. Med. 36:1301-6
103. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-73
104. Yao CH, Fowle-Grider R, Mahieu NG, Liu GY, Chen YJ, et al. 2016. Exogenous fatty acids are the preferred source of membrane lipids in proliferating fibroblasts. Cell Chem. Biol. 23:483-93
105. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, et al. 2012. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149:656-70
106. Young JD. 2014. INCA: A computational platform for isotopically non-stationary metabolic flux analysis. Bioinformatics 30:1333-35
107. Young RM, Ackerman D, Quinn ZL, Mancuso A, Gruber M, et al. 2013. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev. 27:1115-31
108. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, et al. 2012. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15:157-70
109. Zhao H, Yang L, Baddour J, Achreja A, Bernard V, et al. 2016. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. eLife 5:e10250